In the former scenario, it appears to result from drug-associated induction of a cytotoxic T-cell mediated anti-melanoma immune response, where target antigens are expressed on both melanoma cells and normal melanocytes (e.g., MART-1, GP100, TRP1-2, tyrosinase). The gene discussed is TRPV4; the disease is melanoma.